Conference Proceedings
ROR1 is associated with ovarian cancer progression and chemoresistance.
Dongli Liu, Miya John, Claire E Henry, Elizabeth L Christie, David DL Bowtell, Kristina Tang, Viola Heinzelmann-Schwarz, Catherine Kennedy, Jessica Boros, Anna DeFazio, Caroline E Ford
CLINICAL CANCER RESEARCH | AMER ASSOC CANCER RESEARCH | Published : 2020
Abstract
Abstract Background: New targets for ovarian cancer treatment are critically needed. The Wnt receptors ROR1 and ROR2 are overexpressed in all subtypes of ovarian cancer and appear to play a role in both the tumor and surrounding microenvironment (1). In vitro studies support the approach of targeting these receptors together to inhibit ovarian cancer migration and invasion (2, 3). Aim: To investigate the role of ROR1 and ROR2 in ovarian cancer progression, survival and chemoresistance, to determine their feasibility as therapeutic targets. Methods: Analysis of RNA-Seq data from publicly available ovarian cancer datasets was performed to determine ..
View full abstract